Qiagen, NL0012169213

Qiagen N.V. highlights its role in molecular diagnostics as investors track the stock

Veröffentlicht: 05.07.2026 um 11:52 Uhr, Redaktion AD HOC NEWS, Redaktionelle Verantwortung: Rafael Müller (Chefredaktion)

Qiagen N.V. is a key player in sample preparation and molecular diagnostics, and its stock reflects expectations for long-term demand in life science and clinical testing applications.

Qiagen, NL0012169213
Qiagen, NL0012169213

Qiagen N.V. (ISIN NL0012169213) is a global provider of sample and assay technologies used to transform biological materials into valuable molecular information, serving customers across research, clinical diagnostics, pharmaceutical development, and applied testing.

As a company active in molecular diagnostics and life sciences, Qiagen develops integrated solutions that enable laboratories to extract, process, and analyze DNA, RNA, and proteins from a wide range of samples.

Business profile and market positioning

Qiagen focuses on technologies that streamline workflows from sample collection through analysis, aiming to make complex molecular testing more accessible and reproducible for laboratories of different sizes.

Its portfolio spans instruments, consumables, and software that can be combined into standardized workflows, supporting repeatable test results for research projects and routine diagnostic procedures.

Demand drivers in diagnostics and research

Demand for Qiagen's solutions is closely linked to trends in molecular research, personalized medicine, infectious disease testing, and oncology, where laboratories require reliable tools for sample preparation and analysis.

In clinical environments, standardized workflows and validated assay systems are important for turning patient samples into clear molecular test results that can support medical decision-making.

Go deeper

Further information on Qiagen N.V.

Investors and interested readers can find more structured information on the company and its investor materials via external portals and corporate publications.

Representative product and workflow role

One representative area of Qiagen's business is its sample preparation kits and associated instruments, which are designed to help laboratories purify nucleic acids from blood, tissue, cell cultures, or other materials in a consistent and efficient manner.

Stock context and listing

Qiagen N.V. is listed as a public company, and its stock provides investors with exposure to the molecular diagnostics and life science tools segment without tying the investment to a single therapeutic area.

Qiagen N.V. key data

  • Company: Qiagen N.V.
  • ISIN: NL0012169213
  • Ticker: [symbol]
  • Exchange: [listing venue]
  • Price (as of [date and time ET]): [latest available price and currency]
  • Market cap: [latest available value and currency] (as of [date])
  • Sector / Industry: Life science tools and molecular diagnostics
  • Index membership: [major index, if applicable]
  • Next earnings date: Not yet officially scheduled

Social media and video search

This article was generated automatically and technically reviewed before publication. Market prices, analyst data and company information are provided without warranty and may change at short notice. This content is for informational purposes only and is not investment, financial, legal or tax advice. It is not a recommendation to buy or sell any security. Investing in securities involves risk, including the possible loss of principal.

en | NL0012169213 | QIAGEN | boerse | 69695348 | bgmi